{
    "Trade/Device Name(s)": [
        "VIDAS\u00ae NEPHROCHECK\u00ae",
        "VIDAS NEPH"
    ],
    "Submitter Information": "bioM\u00e9rieux SA",
    "510(k) Number": "K210793",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171482"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PIG"
    ],
    "Summary Letter Date": "March 3, 2022",
    "Summary Letter Received Date": "March 7, 2022",
    "Submission Date": "March 15, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1220"
    ],
    "Regulation Name(s)": [
        "Acute Kidney Injury Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "toxicology"
    ],
    "Analyte(s)": [
        "TIMP-2",
        "IGFBP-7"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "LBP-treated tube",
        "plastic tube with no additive"
    ],
    "Instrument(s)/Platform(s)": [
        "VIDAS\u00ae 3 instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked fluorescent assay (ELFA)",
        "Labeled antibody competition method"
    ],
    "Methodologies": [
        "Immunoenzymatic quantitative determination"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Calibrator",
        "Control",
        "Reagent",
        "Strip"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS NEPHROCHECK\u00ae automated immunoassay for quantitative determination of TIMP-2 and IGFBP-7 in urine on the VIDAS\u00ae 3 instrument to assess acute kidney injury risk.",
    "Indications for Use Summary": "Intended for use in adult ICU patients (21+ years) with recent acute cardiovascular or respiratory compromise as an aid in risk assessment for moderate or severe acute kidney injury within 12 hours, in conjunction with clinical evaluation.",
    "fda_folder": "Clinical Chemistry"
}